Patent classifications
G01N33/5308
METHODS AND KITS FOR PREDICTING INFUSION REACTION RISK AND ANTIBODY-MEDIATED LOSS OF RESPONSE BY MONITORING SERUM URIC ACID DURING PEGYLATED URICASE THERAPY
Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response during intravenous PEGylated uricase therapy in gout patients is provided. Routine SUA monitoring can be used to identify patients receiving PEGylated uricase who may no longer benefit from treatment and who are at greater risk for infusion reactions.
CHEMICAL COMPOSITIONS AND METHODS OF USE
The present invention is directed to methods for detecting a melanoma, methods for determining whether a melanoma is stable or progressive, methods for evaluating the extent of surgery resection in a subject having a melanoma, and methods for determining a response by a subject having a melanoma to a therapy.
Kits and methods for the enrichment and detection of RNA viruses of the Coronaviridae family
Kits and methods for the detection and enrichment of RNA viruses of the family Coronaviridae. The detection method comprises the steps of (a) coupling a binding agent that specifically recognizes and binds to a virus component to a carrier material, (b) incubating the carrier material with the thereon coupled binding agent with a virus-containing sample, (c) staining the viruses immobilised on the carrier material with a staining agent, and (d) detecting stained virus particles via a physical, chemical or biological detection means. The methods may be suitable for the rapid and efficient detection of coronaviruses, such as SARS-CoV-2. With the methods and kits, it is possible to perform rapid high-throughput tests in a large population. At the same time, the enrichment procedure makes it possible to enrich viral samples, e.g. from a throat swab of a patient, for use in a subsequent PCR.
DRY EYE DISEASE BIOMARKERS AND THEIR USE FOR TREATMENT
The present invention relates to use of biomarkers of dry eye disease, and use of the biomarkers for selection of subjects for treatment and treatment of dry eye disease.
NOVEL INSECT INHIBITORY PROTEINS
Pesticidal proteins exhibiting toxic activity against Lepidopteran pest species are disclosed, and include, but are not limited to, TIC6757, TIC6757PL, TIC7472, TIC7472PL, TIC7473, and TIC7473PL. DNA constructs are provided which contain a recombinant nucleic acid sequence encoding one or more of the disclosed pesticidal proteins. Transgenic plants, plant cells, seed, and plant parts resistant to Lepidopteran infestation are provided which contain recombinant nucleic acid sequences encoding the pesticidal proteins of the present invention. Methods for detecting the presence of the recombinant nucleic acid sequences or the proteins of the present invention in a biological sample, and methods of controlling Lepidopteran species pests using any of the TIC6757, TIC6757PL, TIC7472, TIC7472PL, TIC7473, and TIC7473PL pesticidal proteins are also provided.
Isolated monoclonal antibodies and/or antigen-binding fragments thereof against indoxyl sulfate and uses thereof
The present invention relates to isolated monoclonal antibodies (mAbs) and/or antigen-binding fragments thereof that specifically recognize indoxyl sulfate, a protein-bound uremic toxin, and uses of such isolated anti-IS mAbs and/or antigen-binding fragments thereof to create immunoassay methods applied in theragnosis of IS-related diseases.
Surface modified electrodes, and methods of preparation thereof
A surface modified electrode is provided. The surface modified electrode includes a glassy carbon electrode (GCE) and a nanomaterial disposed on the glassy carbon electrode. The nanomaterial comprises carbon nanotubes (CNTs), and at least one of thallium oxide nanoparticles (Tl.sub.2O.sub.3.NPs), thallium oxide (Tl.sub.2O.sub.3) nanopowder, and thallium oxide carbon nanotube nanocomposites (Tl.sub.2O.sub.3.CNT NCs). A polymer matrix is configured to bind the glassy carbon electrode with the nanomaterial. A method of preparing the surface modified electrode is also disclosed. The surface modified electrode can be implemented in a biosensor for detecting a biological molecule, like choline.
SURFACE MODIFIED ELECTRODES, AND METHODS OF PREPARATION THEREOF
A surface modified electrode is provided. The surface modified electrode includes a glassy carbon electrode (GCE) and a nanomaterial disposed on the glassy carbon electrode. The nanomaterial comprises carbon nanotubes (CNTs), and at least one of thallium oxide nanoparticles (Tl.sub.2O.sub.3.Math.NPs), thallium oxide (Tl.sub.2O.sub.3) nanopowder, and thallium oxide carbon nanotube nanocomposites (Tl.sub.2O.sub.3.Math.CNT NCs). A polymer matrix is configured to bind the glassy carbon electrode with the nanomaterial. A method of preparing the surface modified electrode is also disclosed. The surface modified electrode can be implemented in a biosensor for detecting a biological molecule, like choline.
NOVEL CORONAVIRUS NUCLEIC ACID RAPID HYBRID CAPTURE IMMUNOFLUORESCENCE DETECTION KIT, AND PREPARATION METHOD AND DETECTION METHOD THEREOF
The invention relates to the technical field of nucleic acid detection and discloses a novel coronavirus nucleic acid rapid hybrid capture immunofluorescence detection kit, and a preparation method and a detection method thereof. The kit includes a COVID-19 reaction solution, wherein the COVID-19 reaction solution is prepared from a COVID-19 fluorescence marker and a COVID-19 probe solution; and the COVID-19 probe solution includes: an ORFlab section probe, an N section probe and an E section probe. Compared with general fluorescence PCR and sequencing detection, the kit has the advantages of stronger signal intensity, better specificity, shorter detection time, no need of professional technicians for operation, no need of refrigeration in transportation and storage, no need of a matched laboratory and a matched PCR instrument, and convenience and rapidness in use.
Liquid Chromatography Assay for Determining AAV Capsid Ratio
Methods for determining the relative abundance of intact adeno-associated virus (AAV) capsid components in a sample of recombinant AAV particles are disclosed. In embodiments, the methods include a system regeneration process that minimizes or eliminates the presence of ghost peaks to maximize analytical accuracy and ensure product quality and consistency.